Sutro Biopharma (STRO) Operating Margin (2017 - 2025)
Historic Operating Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 499.94%.
- Sutro Biopharma's Operating Margin rose 2972300.0% to 499.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.53%, marking a year-over-year decrease of 1125600.0%. This contributed to the annual value of 384.34% for FY2024, which is 3262600.0% down from last year.
- Per Sutro Biopharma's latest filing, its Operating Margin stood at 499.94% for Q3 2025, which was up 2972300.0% from 5.25% recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's Operating Margin registered a high of 37.95% during Q4 2023, and its lowest value of 1202.0% during Q1 2025.
- Moreover, its 5-year median value for Operating Margin was 333.26% (2023), whereas its average is 365.27%.
- Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 6081700bps in 2023, then crashed by -7669500bps in 2025.
- Over the past 5 years, Sutro Biopharma's Operating Margin (Quarter) stood at 328.85% in 2021, then tumbled by -73bps to 570.23% in 2022, then surged by 107bps to 37.95% in 2023, then crashed by -1261bps to 440.66% in 2024, then fell by -13bps to 499.94% in 2025.
- Its Operating Margin stands at 499.94% for Q3 2025, versus 5.25% for Q2 2025 and 1202.0% for Q1 2025.